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Comment on ‘Inserting the etonogestrel contraceptive implant’ 
 
We were most interested to read the letter from Dr Martyn Walling about the insertion technique 
for the etonogestrel implant.1 We too have adopted his technique of injecting local anaesthetic only 
at the site of needle puncture and not along the length of the proposed track. We also agree with 
Walling that after the needle has penetrated the dermis it should be withdrawn until the bevel is 
seen and then insertion continued after the angle of the needle has been adjusted to parallel to the 
skin surface. Some argue against the former on the grounds that the insertion will be more painful, 
but most of the pain experienced is when the skin is penetrated. We have however noticed that the 
the last 1cm of insertion is, for some unknown reason, often painful at the tip. 
We feel Walling did not make himself entirely clear about the reasons for the above techniques. He 
refers generally to impalpable implants: in fact he is conflating two different problems, namely 
deeply located implants and absent implants (non-insertion). The FSRH guidance should be carefully 
noted: an impalpable implant should not be assumed to be a deep implant.2 We would like to make 
comments on both deep insertions and non-insertion. 
Deeply located implants create difficulties with removal. They can be prevented by the manoeuvre 
Walling describes and by tenting the skin throughout the whole insertion process.  
One of the predisposing factors for complications of deep contraceptive implant insertions is the 
‘thin arm’.3 In women with a substantial layer of subcutaneous fat in the arm, a deeply inserted 
implant is unlikely to injure vital structures; it may need removal by an expert but is unlikely to result 
in serious complications.  In contrast in a slim arm, a less deeply inserted implant can still easily 
penetrate the muscle fascia.  In the thin arm, the neurovascular bundle is close to the surface and 
can easily be injured during a slightly deep insertion.4;5 
Experience from clinical cases and medicolegal cases has shown repeatedly that unless particular 
care is taken with tenting the skin and keeping superficial in women with thin arms, implants can 
penetrate muscle fascia. Once part of the implant is inside the muscle (biceps or triceps), muscle 
contractions can rapidly force the remainder of the implant into the muscle; migration up or down 
the muscle is then possible. Implants in such a location are best referred to a specialist centre (MSD 
holds a list of recognised Centres).  Rarely such cases have had to undergo removal by open surgery 
under general anaesthesia rather than the usual techniques under local anaesthesia. Outcomes such 
as this are prone to trigger litigation. 
It must be emphasised that the modifications to the etonogestrel implant introducer in 20106 have 
not done away with deep insertions. Deep insertions were already being noted in preliminary trials 
of Nexplanon.7 The mechanism situated just above the needle of Nexplanon is not sufficient in itself 
to set the depth of the implant; tenting of the skin is still necessary. The tip of the needle under the 
dermis should be observed directly throughout the insertion procedure. Unfortunately visualisation 
of the needle during insertion is restricted because the ‘nose’ of the applicator obscures the view.6 
The needle has to be viewed at an angle; a good light source is needed, directed from the side.  
Cases of non-insertion, although rare, continue to be seen.4 These have a completely different 
underlying cause from an impalpable deep implant and have serious implications for the woman 
concerned as she is vulnerable to pregnancy. It appears that the redesign of Implanon into the one-
handed Nexplanon system6 has not stopped non-insertion from happening; we are still seeing 
medicolegal cases of non-insertion. What is troubling is that these cases are not being picked up by 
the clinicians concerned even though they go through the motions of checking the arm for the 
presence of the implant at the end of the insertion procedure. As Walling points out, this may be 
because of being misled by feeling a raised line of local anaesthetic. In some cases it may also be due 
to feeling fibrous tissue from a previous insertion when a subsequent implant is inserted along the 
same track. We recommend placing both ends of the implant between thumb and index finger and 
feeling the bowing of the implant between the digits. 
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